Novo Nordisk Steps Up Production Capacity for GLP-1 Weight-Loss Drugs Amid Intensifying Competition

　　【Pharmaceutical Network Enterprise News】Novo Nordisk, which has been an early player in the weight-loss drug market and owns the first-generation GLP-1 receptor agonist "Liraglutide" and the second-generation GLP-1 receptor agonist "Semaglutide," is now facing competition from its American rival, Eli Lilly. At the beginning of November, regulatory agencies in the United States and the United Kingdom both approved Eli Lilly's diabetes drug Tirzepatide (brand name: Zepbound) for the treatment of obesity. It is reported that the sales revenue of Tirzepatide for diabetes indications reached $1.548 billion in the first half of this year, showing strong performance. Meanwhile, Eli Lilly is actively increasing production, including investing $4 billion to build two factories in North Carolina, striving to double the output of peptide drugs containing Tirzepatide by the end of 2023. One of these factories has already started production.
 

Against this backdrop, Novo Nordisk has made another significant move by ramping up the production of weight-loss drugs. For instance, recently, Novo Nordisk announced an investment of over 16 billion Danish kroner (approximately 16.8 billion yuan) to expand its existing production facilities for severe chronic disease-related pharmaceutical products in Loire, France. The relevant construction projects are expected to be completed between 2026 and 2028, which will increase the production capacity of various products, including several types of GLP-1 products.
 

On November 10, Novo Nordisk announced plans to invest over 42 billion Danish kroner (approximately 44.1 billion yuan) starting this year to expand its factories in Denmark for the production of its current and future portfolio of products targeting serious chronic diseases. This investment will enhance its capacity to meet future market demand, including for GLP-1 products.
 

Previously in June, Novo Nordisk announced plans to invest 15.9 billion Danish kroner (approximately 16.697 billion yuan) starting from 2023 to expand the company's existing facilities in Denmark.Active Pharmaceutical Ingredients(API) production facilities to enhance Novo Nordisk's ability to meet future market demands and also lay the groundwork for its future product portfolio in the field of serious chronic diseases.
 

It is reported that the construction projects will start from the end of 2025 and be completed by 2029. To meet current market demands, Novo Nordisk mentioned in its Q1 financial report this year that two new CMO production lines will be added this year. In April this year, the second contract manufacturer for Wegovy began production, which will enhance the supply capacity of Wegovy.
 

It can be seen that Novo Nordisk will actively expand the production of semaglutide to enhance its market competitiveness. So far, there are three formulations of semaglutide on the market: Ozempic (injectable hypoglycemic drug), Rybelsus (oral hypoglycemic drug), and Wegovy (injectable weight-loss drug). In the first half of this year, the total sales of these three products reached 9.051 billion US dollars, which is close to the total sales of 10.9 billion US dollars in 2022. In the first three quarters, due to the popularity of the "weight loss" indication, the cumulative sales of the three formulations of semaglutide further increased to 14.282 billion US dollars. Among them, the sales of Wegovy, which has a weight loss indication, were approximately 3.1 billion US dollars, with a growth rate of 481%. Only in the third quarter, the sales of Wegovy reached 1.36 billion US dollars.
 

Notably, in terms of pricing, Eli Lilly announced that the price of tirzepatide will be set at approximately $1,060 per month, which is 20% lower than Novo Nordisk's semaglutide (Wegovy), potentially giving it a competitive edge in terms of cost. Reportedly, the monthly cost of Wegovy in the United States is over $1,300, and about half of American commercial insurers have yet to include it in their coverage; it is also not covered by Medicare.
 

As pressure mounts from Eli Lilly's tirzepatide, Novo Nordisk is reportedly set to negotiate with healthcare systems in certain countries, with the core discussion revolving around an innovative pricing agreement for its weight-loss drug Wegovy. The company aims to use this agreement to help healthcare providers spread the cost over multiple years, thereby enhancing Wegovy's competitiveness.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.